頁籤選單縮合
| 題 名 | 長照中心住民COVID-19疫苗施打概論=COVID-19 Vaccines for Long-term Care Residents |
|---|---|
| 作 者 | 王宇平; 王雅芳; | 書刊名 | 長照感染預防控制雜誌 |
| 卷 期 | 1:1 2022.06[民111.06] |
| 頁 次 | 頁21-25 |
| 分類號 | 418.293 |
| 關鍵詞 | COVID-19疫苗; 長照中心; COVID-19 vaccines for long-term care residents; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | COVID-19 是由 SARS-CoV2 病毒引起的感染性疾病。從 2019 年底在中國武漢疫情爆發以 來,已經造成全球超過 5 億人感染,630 萬以上的死亡。對於長照中心的住民來說,因為年齡 較大共病症多,此一衝擊更是嚴重。COVID-19 疫苗的出現,能大幅降低 COVID-19 造成的住院 和死亡,因此長照中心人員的疫苗施打更是十分重要。疫苗的有效性和安全性當然是施打疫苗 選擇的重要考量。目前在台灣有腺病毒載體疫苗 (AstraZeneca- ChAdOx1),mRNA 疫苗(BioNTech-BNT162b2 及 Moderna-mRNA1273)和次蛋白疫苗(高端 MVC-COV1901)可以做選 擇。本文將針對疫苗的施打做一個簡單的概論。 |
| 英文摘要 | COVID-19 is an infectious disease caused by virus SARS-CoV2. Since the outbreak in Wuhan, China in 2019, there were more than 500 million confirmed cases and 6.3 million deaths. For longterm care facility residents, the impact is more serious because the residents are older and have more comorbidities. COVID-19 vaccination can decrease the hospitalization and death of COVID-19 significantly, so it is important for the long-term care facility residents and staffs to receive vaccination. The efficacy and safety is the main concern for vaccination. Currently we have four type of COVID-19 available in Taiwan, adenovector vaccine (AstraZeneca- ChAdOx1), mRNA vaccine(BioNTechBNT162b2 and Moderna-mRNA1273) and protein subunit with adjuvant vaccine (Medigen MVCCOV1901). In this review, we will introduce the COVID-19 vaccination. |
本系統中英文摘要資訊取自各篇刊載內容。